Lexicon Pharmaceuticals/$LXRX
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Lexicon Pharmaceuticals
Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, and LX9851, an orally-delivered small molecule drug candidate, as a treatment for obesity and associated cardiometabolic.
- Ticker
- $LXRX
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 81
- Headquarters
- The Woodlands, United States
- Website
- www.lexpharma.com
LXRX Metrics
BasicAdvanced
$632M
-
-$0.16
1.03
-
Price and volume
Market cap
$632M
Beta
1.03
52-week high
$2.68
52-week low
$1.10
Average daily volume
2.6M
Financial strength
Current ratio
13.367
Quick ratio
13.073
Long term debt to equity
0.33
Total debt to equity
0.339
Interest coverage (TTM)
-6.50%
Profitability
EBITDA (TTM)
-54.023
Gross margin (TTM)
86.02%
Net profit margin (TTM)
-147.38%
Operating margin (TTM)
-131.43%
Revenue per employee (TTM)
$510,000
Management effectiveness
Return on assets (TTM)
-14.32%
Return on equity (TTM)
-40.21%
Valuation
Price to revenue (TTM)
13.397
Price to book
3.62
Price to tangible book (TTM)
4.86
Price to free cash flow (TTM)
-8.549
Free cash flow yield (TTM)
-11.70%
Free cash flow per share (TTM)
-0.166
Growth
Revenue change (TTM)
-29.03%
Earnings per share change (TTM)
-52.32%
3-year revenue growth (CAGR)
367.06%
10-year revenue growth (CAGR)
-12.65%
3-year earnings per share growth (CAGR)
-38.72%
10-year earnings per share growth (CAGR)
-2.65%
What the Analysts think about LXRX
Analyst ratings (Buy, Hold, Sell) for Lexicon Pharmaceuticals stock.
Analyst projections of the future price of Lexicon Pharmaceuticals stock.
Bulls say / Bears say
Lexicon has completed and substantially over-enrolled its pivotal Phase 3 SONATA-HCM trial, with a majority of participants having non-obstructive HCM, where treatment options are limited. Top-line results are expected in the first quarter of 2027. (Lexicon Pharmaceuticals)
Novo Nordisk has advanced the obesity drug LX9851 into Phase 1 and triggered a third $10 million milestone payment to Lexicon in 2026. Lexicon has received $75 million so far and could earn further milestones and royalties if the drug progresses and reaches the market. (Lexicon Pharmaceuticals)
The company reported $190.6 million in cash and investments at the end of June 2026 and said this, alongside expected collaboration cash and revenue, should fund planned operations for at least 12 months from its latest quarterly report. (SEC)
SONATA-HCM remains a high-stakes clinical test: the pivotal trial has yet to report results, which Lexicon expects in the first quarter of 2027. A disappointing read-out could undermine its main near-term growth opportunity. (Lexicon Pharmaceuticals)
The type 1 diabetes application still faces regulatory uncertainty: the FDA issued complete response letters in the past, and Lexicon says a resubmission depends on safety and exposure data from the ongoing STENO-1 study. The company also disclosed that FDA proceedings on whether to deny the application are ongoing. (SEC)
Commercial sales remain very small relative to the cost base: Lexicon reported just $0.7 million in total second-quarter revenue and a $31.8 million net loss. It remains dependent on future clinical progress, partnerships and financing rather than established product income. (SEC)
Data summarised monthly by Lightyear AI. Last updated on 25 Oct 2026.
LXRX Financial Performance
Revenues and expenses
LXRX Earnings Performance
Company profitability
Upcoming events
No upcoming events
LXRX News
AllArticlesVideos
Funds containing LXRX
Fund name | Fund size | $LXRX weighting |
|---|---|---|
SPDR Russell 2000 US Small Cap£R2SC | $5.3B | 0.01% |
SPDR Russell 2000 US Small Cap€R2US | $5.3B | 0.01% |
Xtrackers MSCI World Small Cap$XSWC | $183M | 0.00% |
SPDR MSCI All Country World IM€SPYI | $7.7B | 0.00% |
iShares MSCI USA Small Cap ESG Enhanced CTB€SXRG | $3.2B | 0.00% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.